Viloxazine Under Review for ADHD Treatment in Adults

 ADHD in the News 2021-09-09

The Food and Drug Administration has accepted for review the supplemental New Drug Application for viloxazine extended-release for the treatment of attention-deficit hyperactivity disorder in adults...Viloxazine is currently marketed under the trade name Qelbree and is indicated for the treatment of ADHD in patients 6 to 17 years of age.